A Phase II study found that patients with ACE inhibitor-induced angioedema who received ecallantide were more likely to be discharged sooner than those treated with antihistamines and steroids. Read more.

A Phase II study found that patients with ACE inhibitor-induced angioedema who received ecallantide were more likely to be discharged sooner than those treated with antihistamines and steroids. Read more.